that the drug did not meet patentability standards as imposed by the Indian Patent Act's Section 3(d) regarding "incremental innovation" and limiting patent protection to what is specifically disclosed, again in contradiction to global norms, it said.
"This is despite Glivec being recognised as a breakthrough drug and given protection in 40 jurisdictions around the world.
"Given the prominence and size of India's generic pharmaceutical industry, other countries have taken notice and begun to introduce similar provisions into their own laws and regulations," said David Hirschmann, President and CEO of the GIPC.
"A robust IP system provides the critical foundation needed for nations wishing to advance their economic and social progress, and provide assurances to consumers that the products they use are authentic, safe, and effective," said Hirschmann.
"By highlighting countries that are leading or lagging in fostering a strong IP framework, the GIPC Index provides a clear and objective tool for policy makers to strengthen innovative potential and for business leaders to assess risk and investment," he added.
According to Hirschmann, the United States may lead the overall ranking, but has fallen behind in its enforcement efforts.
"Therefore, we urge the Obama administration and Congress to expand on current enforcement programs and allocate dedicated resources throughout the government to effectively enforce IP rights and protect consumers," he said.